ReviewFrontiers in immunology2026
Immunomodulation by glycosylation: bridging glycobiology to adaptive immunity and therapeutic innovation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adaptive immunity provides specific and long-lasting protection through antigen-specific responses and immune memory, a property that has been successfully harnessed in transformative immunotherapies. Advancing these treatments requires a deeper understanding of the molecular mechanisms that fine-tune immune activity. In this context, glycosylation, a ubiquitous and complex post-translational modification, is emerging as a central regulator. By shaping the structure and function of immune proteins, glycans critically regulate the behavior of T cells, B cells and antigen-presenting cells. This review summarizes current knowledge on how glycosylation governs key processes in acquired immunity, from antigen recognition and immune signal transduction to cell-cell interaction. We highlight that glycans can function directly as antigens or, more commonly, by forming distinct glyco-signatures on cell surfaces that sculpt immune response. Furthermore, we discuss the therapeutic implications of these insights and outline emerging strategies that target glycosylation pathways to enhance anti-tumor immunity, improve vaccine efficacy, and treat autoimmune disorders. A deeper integration of glycobiology into adaptive immunity is therefore pivotal for developing the next generation precision immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.